Close Menu

NEW YORK (GenomeWeb) – The US Food and Drug Administration announced today it  approved Qiagen's Therascreen FGFR RGQ RT-PCR Kit as a companion diagnostic for Janssen Pharmaceutical's metastatic bladder cancer drug erdafitinib (Balversa) in a molecularly defined subpopulation.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.